Saratov JOURNAL of Medical and Scientific Research

Prognostic significance of the assessment of the expression of immunohistochemical markers and the degree of pathomorphism before and after treatment of patients with prostate cancer at high risk of progression

Year: 2019, volume 15 Issue: №2 Pages: 318-324
Heading: Urology Article type: Original article
Authors: Voronina E.S. , Fomkin R.N. , Bucharskaya A.B. , Palatova T.V. , Popkov V.M., Maslyakova G.N.
Organization: Saratov State Medical University

Purpose: to analyze the expression of immunohistochemical markers in patients with prostate adenocarcinoma at high risk of progression before and after combined and combined treatment of patients with prostate specific antigen (PSA) level of blood below discriminatory. Material and methods. Examined patients (n = 80) with a diagnosis of “High-risk progression prostate cancer,” with clinical stage T3a, total score for Gleason scale from 8 to 10, the level of total PSA more than 20 ng / ml. Patients of the 1st group (n = 42) only combined surgical treatment in the scope of TUR and HIFU ablation the prostate; The 2nd group of patients (n = 38) additionally applied androgen deprivation in adjuvant mode. Results. Blood PSA, determined in patients after various methods of treatment is not always an objective indicator of its effectiveness. Immunohistochemical studies of tumor tissue for proliferative activity tumor cells, the activation of apoptosis in them, as well as the assessment of specific tumor markers and tumor suppressor genes showed that a decrease in the expression of these markers in patients with PSA values ​​of blood lower than discriminatory observed in all patients independently on the type of treatment. However, after treatment in the 1st group of patients, despite the achievement PSA level of nadir, there is a decrease in the expression of an intercellular adhesion marker E-cadherin, which indicates an increased risk of tumor metastasis, as well as increased expression of markers of the apoptosis inhibitor Bcl-2 and androgens, which indicates about the possibility of progression of tumor growth. Conclusion For a more accurate assessment therapeutic pathomorphism in patients with prostate cancer at high risk of progression, which HIFU ablation monotherapy was carried out, along with the determination of blood PSA level, it is necessary during the control biopsy of the prostate immunohistochemical studies of tumor tissue to determine the prognosis and risk of relapse.

1 Rusakov IG, Mishutkin SV. Cancer of the prostate gland: trends and perspectives. Medical Council 2017; 14: 78– 81
2 Kaprin AD, Tronov AV, Ivanov SA, Karyakin OB. Complex hormone chemo radiation treatment of patients withnon-metastatic prostate cancer of high and very high risk of progression. Oncourology 2017; 13 (1): 101–11
3 Fomkin RN, Glybochko PV, Popkov VM, Blumberg BI. Treatment of prostate cancer in elderly and senile patients with high-intensity focused ultrasound. Clinical gerontology 2011; 17 (9-10): 27–33
4 D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specifc antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17 (1): 168–72. 5 Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer. European Association of Urology, 2012
6 Shao YH, Demissie K, Shih W, et al. Contemporary risk profle of prostate cancer in the United States. J Natl Cancer Inst 2009; 101 (18): 1280–3
7 Fomkin RN, Popkov VM, Blumberg BI, Bromberg BB. Efectiveness of high-intensity focused ultrasound ablation in the treatment of prostate cancer of high cancer risk. Bulletin of the Russian Military Medical Academy 2013; 44 (4): 55–60
8 Nyushko KM, Alekseev BYa, Krasheninnikov AA, Kaprin AD. Surgical treatment of patients with prostate cancer with a high risk of progression. Oncourology 2014; 10 (2): 38–45
9 Biermann K, Beltran AL, et al. Histopathological results after treatment of prostate cancer using high intensity focused ultrasound (HIFU). Prostate 2010; 11: 1196–200
10 Fomkin RN, Voronina ES, Popkov VM, et al. Pathomorphosis of prostate cancer in the treatment of high-intensity focused ultrasound (HIFU). The Urologic Oncology 2013; 1: 55–62
11 Fomkin RN, Voronina ES, Popkov VM, et al. Prognostic value of molecular biological, morphological and clinical markers in assessing the efectiveness of treatment of localized prostate cancer with high-intensity focused ultrasound. Experimental and clinical urology 2013; 4: 29–33
12 Anand ODE, Satyanarayana RP, Kumar CK, Bhaskar RV. Diagnostic Utility of Immunohistochemical Markers in Prostate Cancer. Journal of Dental and Medical Sciences (IOSR-JDMS) 2017; 16 (3): 22–8
13 Kurzanov AN, Strygina EA, Medvedev VL. Diagnostic and prognostic markers of prostate cancer. Modern problems of science and education. 2016; 2 URL: / ru / article / view?id=24439
14 Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med 2008; 132 (9): 1388–96. DOI: 10.1043 / 1543–2165 (2008)
15 Hameed O, Humphrey PA. Immunohistochemisy in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005; 22 (1): 88–104
16 Gobbo AD, Pellegrinelli A, Gaudioso G, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology 2016; 68 (5): 746–51
17 Saito H, Kitagawa K, Yoneda T, et al. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Therapy 2017; 24: 289–96
18 Gobbo AD, Ferrero S. Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy. Gastroenterology Research and Practice 2017; 2017: 2808235
19 Hsu Y-S, Wang JS, Wu TT. E-Cadherin Expression in Prostate Adenocarcinomas in Chinese and Its Pathological Correlates. Urol Int 2004; 73: 36–40
20 Liu Z-Q, Fang J-M, Xiao Y-Y, et al. Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med 2015; 8 (2): 2289–98.

2019_02_318-324.pdf1.45 MB

No votes yet